Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?

CONCLUSIONS: We documented 7.8% rate of patients with detectable HCV RNA at the ET, of whom 89% subsequently achieved SVR, significantly more frequently in the population treated with pangenotypic regimens. Less severe liver disease, more often GT3 infection, and a higher percentage of treatment-naive patients distinguished this group from non-responders.PMID:37944825 | DOI:10.1016/j.antiviral.2023.105742

Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Dorota Zar ębska-Michaluk Robert Flisiak Ewa Janczewska Hanna Berak W łodzimierz Mazur Justyna Janocha-Litwin Rafa ł Krygier Beata Dobracka Jerzy Jaroszewicz Anna Parfieniuk-Kowerda Krystyna Dobrowolska Piotr Rzymski Source Type: research